<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Preprint: Integrative Multi-Omics Prioritization - Hearing Gene Prioritization</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Merriweather:ital,wght@0,300;0,400;0,700;1,400&family=Inter:wght@400;600&display=swap"
        rel="stylesheet">
    <style>
        :root {
            --primary: #2563eb;
            --text: #1e293b;
            --bg: #f8fafc;
        }

        body {
            font-family: 'Merriweather', serif;
            line-height: 1.8;
            color: var(--text);
            background: var(--bg);
            margin: 0;
            padding: 0;
        }

        header {
            background: #fff;
            padding: 1rem 2rem;
            border-bottom: 1px solid #e2e8f0;
            font-family: 'Inter', sans-serif;
            display: flex;
            justify-content: space-between;
            align-items: center;
            position: sticky;
            top: 0;
            z-index: 100;
        }

        .back-btn {
            text-decoration: none;
            color: var(--primary);
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .container {
            max-width: 800px;
            margin: 3rem auto;
            padding: 0 2rem;
            background: #fff;
            box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            padding: 4rem;
            border-radius: 8px;
        }

        h1 {
            font-size: 2.5rem;
            line-height: 1.2;
            margin-bottom: 1rem;
            color: #0f172a;
        }

        .authors {
            font-family: 'Inter', sans-serif;
            color: #64748b;
            margin-bottom: 3rem;
            font-size: 1.1rem;
        }

        h2 {
            font-family: 'Inter', sans-serif;
            font-weight: 700;
            margin-top: 2.5rem;
            color: #334155;
            border-bottom: 2px solid #f1f5f9;
            padding-bottom: 0.5rem;
        }

        p {
            margin-bottom: 1.5rem;
            font-size: 1.125rem;
        }

        ul {
            margin-bottom: 1.5rem;
        }

        li {
            margin-bottom: 0.5rem;
        }

        .abstract-box {
            background: #f8fafc;
            padding: 2rem;
            border-left: 4px solid var(--primary);
            margin-bottom: 3rem;
            border-radius: 0 8px 8px 0;
        }

        .abstract-title {
            font-family: 'Inter', sans-serif;
            font-weight: 700;
            text-transform: uppercase;
            font-size: 0.875rem;
            color: var(--primary);
            margin-bottom: 1rem;
            display: block;
        }

        code {
            background: #f1f5f9;
            padding: 0.2rem 0.4rem;
            border-radius: 4px;
            font-family: monospace;
            font-size: 0.9em;
        }

        .figure-ref {
            color: var(--primary);
            font-weight: bold;
        }

        @media (max-width: 768px) {
            .container {
                padding: 2rem;
                margin: 0;
                border-radius: 0;
            }

            h1 {
                font-size: 2rem;
            }
        }
    </style>
</head>

<body>

    <header>
        <a href="index.html" class="back-btn">← Back to Dashboard</a>
        <span style="color: #94a3b8; font-size: 0.9rem;">PREPRINT • 2025</span>
    </header>

    <article class="container">
        <h1>Integrative Multi-Omics Prioritization of Therapeutic Targets for Sensorineural Hearing Loss</h1>

        <div class="authors">
            Omer Ozmen, et al.<br>
            <span style="font-size: 0.9rem; color: #94a3b8;">Department of Translational Medicine, Uludag University,
                Türkiye
                Institute</span>
        </div>

        <div class="abstract-box">
            <span class="abstract-title">Abstract</span>
            <p><strong>Background:</strong> Sensorineural hearing loss affects millions worldwide, yet identifying
                optimal therapeutic targets remains challenging due to the complexity of inner ear biology. Existing
                approaches often lack integration across development, aging, and species conservation.</p>
            <p><strong>Methods:</strong> We developed a Therapeutic Priority Score (TPS) pipeline integrating
                single-nucleus RNA-seq data from human (GSE213796) and mouse (GSE114157, GSE60019, GSE274279) inner
                ears. We scored genes based on hair cell specificity, developmental peak expression, aging-related
                decline, cross-species conservation, and GWAS support. We further integrated noise-injury response data
                and druggability metrics (pLI, localization) to refine the candidate list.</p>
            <p><strong>Results:</strong> Our analysis prioritized 72,655 genes, identifying <em>OTOF</em>,
                <em>SLC26A5</em>, and <em>MYO7A</em> as top therapeutic candidates. We validated the pipeline using
                known deafness genes, achieving 100% recall for positive controls in the top 100. Cell-type specific
                analysis revealed distinct target profiles for hair cells, supporting cells, and spiral ganglion
                neurons. Pathway enrichment analysis for the top 50 candidates did not yield statistically significant
                terms (FDR < 0.05), suggesting a functional diversity among the prioritized targets. </p>
                    <p><strong>Conclusion:</strong> This study provides a robust, data-driven framework for prioritizing
                        hearing
                        loss targets. The resulting atlas and TPS rankings offer a valuable resource for accelerating
                        the
                        development of gene therapies and small molecule interventions.</p>
        </div>


        <h2>Introduction</h2>
        <p>Sensorineural hearing loss (SNHL) is a prevalent sensory deficit, yet pharmacological treatments remain
            elusive. The inner ear's complexity, with its diverse cell types and intricate developmental programs, poses
            a significant barrier to target identification. While individual datasets exist, a unified framework
            integrating human and mouse data across lifespan is lacking.</p>
        <p>In this study, we present a comprehensive multi-omics atlas and a novel Therapeutic Priority Score (TPS) to
            systematically rank potential targets. By synthesizing data from development, maturation, and aging, we aim
            to identify genes that are not only essential for hearing but also amenable to therapeutic intervention.</p>

        <h2>Methods</h2>
        <h3>Data Acquisition and Processing</h3>
        <p>We obtained public single-cell and bulk RNA-seq datasets from GEO:</p>
        <ul>
            <li><strong>Human:</strong> GSE213796 (Kelley et al.), comprising fetal and adult inner ear samples.</li>
            <li><strong>Mouse Mature:</strong> GSE114157 (Yamashita et al.), sorted hair cells.</li>
            <li><strong>Mouse Development:</strong> GSE60019 (Scheffer et al.), bulk RNA-seq time series (E16-P7).</li>
            <li><strong>Mouse Aging:</strong> GSE274279 (Xia et al., 2025), aging cochlea and utricle.</li>
        </ul>
        <p>Raw counts were processed using Scanpy (v1.9). Data were log-normalized (<code>log1p</code>) and scaled.
            Cross-species integration was performed using ortholog mapping via Ensembl Biomart.</p>

        <h3>Therapeutic Priority Score (TPS) Calculation</h3>
        <p>We defined the TPS as a weighted sum of five biological metrics:</p>
        <ol>
            <li><strong>HC Specificity:</strong> Difference in mean expression between hair cells and non-sensory cells
                in the human atlas.</li>
            <li><strong>Developmental Peak:</strong> 99th percentile expression during mouse development, prioritizing
                genes essential for maturation.</li>
            <li><strong>Aging Decline:</strong> Fold-change difference between young and aged mouse samples.</li>
            <li><strong>Conservation:</strong> Correlation of expression profiles between human and mouse orthologs.
            </li>
            <li><strong>GWAS Support:</strong> Binary indicator based on curated hearing loss loci.</li>
        </ol>
        <p>The score was calculated as a weighted sum. Advanced integration incorporated noise
            injury response and druggability metrics (pLI scores, subcellular localization).</p>

        <h2>Results</h2>
        <h3>A Multi-Species Atlas of the Inner Ear</h3>
        <p>We successfully integrated 4 datasets spanning human and mouse lineages. UMAP visualization revealed distinct
            clusters corresponding to hair cells (IHC, OHC), supporting cells, and neurons, conserved across species.
        </p>

        <h3>Identification of High-Priority Therapeutic Targets</h3>
        <p>The TPS pipeline ranked 72,655 genes. The top candidates included well-established deafness genes:</p>
        <ul>
            <li><strong>OTOF (Rank 1):</strong> High specificity and conservation, critical for synaptic transmission.
            </li>
            <li><strong>SLC26A5 (Prestin, Rank 2):</strong> Essential for OHC electromotility.</li>
            <li><strong>MYO7A (Rank 8):</strong> Validated Usher syndrome gene.</li>
        </ul>
        <p>Validation against a curated list of positive controls showed 100% recall in the top 100 genes.</p>

        <h3>Cell-Type Specific Vulnerabilities</h3>
        <p>Deconvolution of scores by cell type identified distinct target sets:</p>
        <ul>
            <li><strong>Hair Cells:</strong> Enriched for <em>MYO6</em>, <em>PTPRQ</em>, <em>TMC1</em>.</li>
            <li><strong>Supporting Cells:</strong> Enriched for <em>GATA3</em>, <em>FGFR3</em>.</li>
            <li><strong>SGN:</strong> Enriched for <em>NEFL</em>, <em>TUBB3</em>.</li>
        </ul>

        <h3>Mechanisms of Aging and Injury</h3>
        <p>Integration of aging data highlighted genes with significant expression decline in aged mice, suggesting
            potential targets for age-related hearing loss (ARHL). Noise-injury integration prioritized genes like
            <em>KCNQ4</em> that are downregulated after trauma, pointing to rescue opportunities.
        </p>

        <section id="tps-v2">
            <h3>Biological Modules</h3>
            <p>We refined the prioritization using specific biological modules:</p>
            <ul>
                <li><strong>HC Regulatory Module:</strong> Correlation with key drivers (Atoh1, Pou4f3, Gfi1).</li>
                <li><strong>SC Plasticity Module:</strong> Correlation with regeneration markers (Sox2, Hes1, Lgr5).
                </li>
                <li><strong>SGN Vulnerability Module:</strong> Specificity to spiral ganglion neurons and noise
                    sensitivity.</li>
                <li><strong>Human Transferability:</strong> Conservation in human organoid atlas.</li>
            </ul>

            <div class="figure-container">
                <img src="results/paper_figures/TPS_Module_Heatmap.png" alt="TPS Module Heatmap">
                <p class="figure-caption"><strong>Figure 5: Module Scores.</strong> Heatmap showing the contribution of
                    each biological module to the top candidate genes.</p>
            </div>

            <div class="figure-container">
                <img src="results/paper_figures/TPS_Top30.png" alt="TPS Final Ranking">
                <p class="figure-caption"><strong>Figure 6: TPS Final Ranking.</strong> The top 30 therapeutic targets
                    based on the weighted sum of biological module scores.</p>
            </div>
        </section>

        <h2>Discussion</h2>
        <p>Our study presents a comprehensive framework for prioritizing hearing loss targets. Unlike previous studies
            that focus on single datasets, our TPS metric integrates specificity, development, aging, and conservation.
            The high ranking of <em>OTOF</em> and <em>SLC26A5</em> validates our approach, while the identification of
            novel targets warrants further experimental validation.</p>
        <p>Limitations include the use of bulk RNA-seq for developmental stages. Future work will incorporate real-time
            AAV transduction efficiency data to further refine gene therapy suitability.</p>

        <h2>Conclusion</h2>
        <p>The TPS framework provides a prioritized roadmap for hearing restoration therapies. By making these results
            accessible via an interactive web dashboard, we aim to accelerate the translation of genomic discoveries
            into clinical treatments.</p>
    </article>

</body>

</html>